DFS was significantly longer among those who received pemetrexed and carboplatin ( PC ) - gefitinib than among those who received PC alone [ hazard ratio ( HR ) , 0.37 ; 95 % confidence interval ( CI ) 0.16-0 .85 ; P = 0.014 ; median , 39.8 vs. 27.0 months ] .